EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-world risk assessment of combined cilostazol-rosuvastatin: a retrospective cohort study using Korean electronic health records

Woo-Young Shin, Ha Young Jang, Kiyoung Lee

Frontiers in Pharmacology · 17.04.2026 · 17

DOI: 10.3389/fphar.2026.1752835 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2026. Verfasst von Woo-Young Shin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Chung-ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cilostazol and rosuvastatin are frequently co-prescribed for cardiovascular disease management, particularly in Asian populations. Despite widespread clinical use, comprehensive real-world safety data for this drug combination remain limited.

Objective

To evaluate the 1-year safety profile of cilostazol-rosuvastatin combination therapy compared with that of cilostazol monotherapy in a real-world Korean population using electronic health records.

Methods

This retrospective cohort study utilised the Observational Medical Outcomes Partnership (OMOP) Common Data Model from Gachon University Gil Hospital (2004–2025). Patients on stable rosuvastatin therapy (≥90 days) who had cilostazol added to their treatment (n = 262) were compared to cilostazol monotherapy patients (n = 6,323). Primary outcomes were incidence of atherosclerotic cardiovascular disease (ASCVD), bleeding, and myopathy at 90 and 365 days. Secondary outcomes included changes in liver enzyme levels and platelet count. Fisher’s exact and Welch’s t-tests were used for statistical analyses.

Results

The combination group had higher baseline comorbidities compared with the monotherapy group, including chronic kidney disease (45.8% vs. 32.1%), diabetes mellitus (55.0% vs. 29.2%), and concurrent antithrombotic therapy (61.1% vs. 27.9%). At the 365-day follow-up, no primary safety events occurred in the combination group (0/113) versus ASCVD 2/2,307 (0.1%), bleeding 3/2,307 (0.1%), and myopathy 1/2,307 (0.0%) in the monotherapy group (p = 1.00). Laboratory parameters remained stable: AST/ALT change +14.0 vs. +5.7 U/L (p = 0.71), platelet change −8.1 vs. +18.0 ×10 9 /L (p = 0.14).

Conclusion

Cilostazol-rosuvastatin combination therapy demonstrated a favourable real-world safety profile despite a higher baseline risk. These findings support the safety of this combination in routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

cilostazoldrug safetyelectronic health recordpharmacovigilancereal-world evidencerosuvastatin

Autor:innen und Institutionen

  • Department of Family Medicine, Chung-ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • College of Pharmacy, Gachon University, Incheon, Republic of Korea.
  • Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea.

Zitieren

APA

Shin, W. Y., Jang, H. Y., & Lee, K. (2026). Real-world risk assessment of combined cilostazol-rosuvastatin: a retrospective cohort study using Korean electronic health records. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1752835

Vancouver

Shin WY, Jang HY, Lee K. Real-world risk assessment of combined cilostazol-rosuvastatin: a retrospective cohort study using Korean electronic health records. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1752835

BibTeX
@article{Shin2026,
  author = {Shin, Woo-Young and Jang, Ha Young and Lee, Kiyoung},
  title = {Real-world risk assessment of combined cilostazol-rosuvastatin: a retrospective cohort study using Korean electronic health records},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1752835}
}
Kostenlos starten →